Physician profile
Jon Hall
NPI 1184723975
$4,477.70
in general payments reported to CMS, 2019-2025
34 companies · $620 in 2025
The $620 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,036 · 2020: $941 · 2021: $489 · 2022: $234 · 2023: $676 · 2024: $481 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,777.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $804.01 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $668.94 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Otsuka America Pharmaceutical, INC. | $502.05 | 2019-2025 | Rexulti, Abilify Maintena |
| Abbvie INC. | $455.47 | 2021-2025 | |
| Pfizer INC. | $300.67 | 2019-2025 | |
| Novo Nordisk INC | $214.97 | 2019-2025 | Rybelsus, Ozempic |
| Amgen INC. | $179.68 | 2019-2025 | Evenity, Repatha, Prolia |
| Glaxosmithkline, LLC. | $176.51 | 2019-2023 | Shingrix, Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $143.41 | 2023-2024 | Camzyos |
| Takeda Pharmaceuticals U.S.A., INC. | $132.22 | 2019-2022 | |
| Lilly USA, LLC | $111.49 | 2019-2024 | Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.62 | 2019-2024 | Jardiance |
| Exact Sciences Corporation | $58.10 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.79 | 2019-2025 | Xifaxan |
| Dexcom, INC. | $52.37 | 2021-2025 | Dexcom G6 Transmitter |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $50.65 | 2019-2020 | |
| Csl Behring | $46.43 | 2025 | Andembry |
| Teva Pharmaceuticals USA, INC. | $45.28 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $41.71 | 2019 | |
| Ironshore Pharmaceuticals INC. | $41.27 | 2020-2023 | Jornay Pm |
| Merck Sharp & Dohme LLC | $36.74 | 2019-2020 | |
| Horizon Therapeutics Plc | $31.49 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $30.99 | 2023 | Gemtesa |
| Shire North American Group INC | $27.64 | 2019 | |
| Corium, LLC | $25.36 | 2025 | Azstarys |
| Eisai INC. | $23.87 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $21.16 | 2025 | |
| Tris Pharma INC | $21.00 | 2025 | Dyanavel Xr |
| Amarin Pharma, INC. | $19.65 | 2020 | |
| Allergan, INC. | $17.74 | 2020 | |
| Vanda Pharmaceuticals INC. | $17.18 | 2025 | Hetlioz, Fanapt |
| Sunovion Pharmaceuticals INC. | $15.88 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.76 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.